Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | DNA2 | P51530 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220855 | 0.90 | MAPT (0.48) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7820257 | 0.81 | KDM4E (0.61) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6537393 | 0.77 | MEN1 (0.54) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11867822 | 0.77 | HAVCR2 (0.70) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL27487163 | 0.77 | HAVCR2 (0.47) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28815874 | 0.77 | KDM4E (0.51) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL6198659 | 0.77 | ALB (0.51) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19220851 | 0.77 | KMT2A (0.47) | ALDH1A1KMT2ALMNATSHRCTSB | |
| SCHEMBL6195248 | 0.76 | HPGD (0.58) | ALDH1A1MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL11869520 | 0.76 | HAVCR2 (0.68) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-02-17 | — | — | US | disclosed |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2020-05-14 | — | — | US | disclosed |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2020-05-14 | — | — | US | disclosed |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2020-02-18 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | MAPT 3303/4885ALDH1A1 3473/4885KDM4E 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.